Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 08/28/25
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources OfficerBusiness Wire • 08/25/25
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in BrazilGlobeNewsWire • 07/31/25
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product SalesZacks Investment Research • 07/29/25
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 07/29/25
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025Business Wire • 07/24/25
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular LymphomaBusiness Wire • 06/18/25